Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial.

ABSTRACT:

Objective

To determine the efficacy and safety of dalteparin postoperative bridging treatment versus placebo for patients with atrial fibrillation or mechanical heart valves when warfarin is temporarily interrupted for a planned procedure.

Design

Prospective, double blind, randomised controlled trial.

Setting

10 thrombosis research sites in Canada and India between February 2007 and March 2016.

Participants

1471 patients aged 18 years or older with atrial fibrillation or mechanical heart valves who required temporary interruption of warfarin for a procedure.

Intervention

Random assignment to dalteparin (n=821; one patient withdrew consent immediately after randomisation) or placebo (n=650) after the procedure.

Main outcome measures

Major thromboem

SUBMITTER: Kovacs MJ 

PROVIDER: S-EPMC8188228 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature